RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Clinical trials for RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) explained in plain language.

Never miss a new study

Get alerted when new RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) trials appear

Sign up with your email to follow new studies for RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

First pill of its kind tested to fight Tough-to-Treat lymphoma

Disease control Recruiting now

This is the first study to test a new oral drug called ARV-393 in people. It aims to see if the drug is safe and if it can help control advanced non-Hodgkin's lymphoma that has come back or stopped responding to other treatments. The drug is designed to break down a specific prot…

Matched conditions: RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Phase: PHASE1 • Sponsor: Arvinas Inc. • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL)

Get alerted when new RELAPSED/REFRACTORY (R/R) ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) trials appear

First pill of its kind tested to fight Tough-to-Treat lymphoma